UK & European Patent Attorney
BSc, PhD (Cantab), EPA, CPA
Craig holds a bachelor’s degree in molecular biology and biochemistry, as well as a PhD in biotechnology. He works on a wide variety of technical subjects, specialising in the fields of biotechnology, biochemistry and life sciences. Craig is recommended in the latest edition of The Legal 500, in which a source commented that he is ‘incredibly helpful and collaborative, helping us efficiently and guiding us through many scenarios to identify key risks and rewards with each strategy’ (2022). Craig has also been noted for being ‘highly knowledgeable’ and noted for his ability to ‘consistently meet incredibly tight deadlines’ (2021). ‘Talented biochemist’ Craig, who ‘garners rave reviews for his life sciences adroitness’ has been recommended in the IAM Patent 1000 guide for the last three years, and is praised for being a ‘lifesaver’ and a ‘true strategic partner’.
Craig’s practice covers diverse biotechnological subject matter, with a particular focus on vaccines, diagnostics, gene therapy, therapeutic antibodies and peptides, and biofuels. Craig has significant experience of European and international patent prosecution, and coordinates global IP strategies for a range of clients including startups, SMEs, universities, large corporations and the UK Government.
Craig gained a first class bachelor’s degree in Molecular Biology and Biochemistry at the University of Durham, where he ranked top in his year. He went on to the University of Cambridge to undertake a PhD in collaboration with a multinational crop research company, focusing on environmental stress tolerance in plants and the interfaces between metabolism and the cell cycle. During his time at Cambridge, Craig was awarded various PhD prizes within the Institute of Biotechnology. He also holds a certificate in Intellectual Property from the University of London as well as an Intellectual Property Litigation Certificate.
Craig has presented on the challenges of stem cell patentability in Europe and provided practical advice on how to obtain commercially-relevant patents in this technical field – a link to the full presentation is available here: European and US Patent Strategies for Cell Therapies.
Memberships & organisations
Craig is a member of CIPA, EPI and has been appointed One Nucleus’ IP Mentor.
Life sciences & chemistry
‘Craig Titmus has been incredibly helpful and collaborative, helping us efficiently and guiding us through many scenarios to identify key risks and rewards with each strategy. It has certainly helped us define and secure our IP as well as getting it through the many hurdles international process patents require.’
‘Craig Titmus pairs the slick management of patent portfolios with an ability to best even the most challenging EPO opposition proceedings. A talented biochemist and an authority on cutting-edge areas like therapeutic antibodies, he is a valuable resource to any life sciences player.’
‘Craig Titmus is a “lifesaver” for his slick management of its fabric dye patent portfolio.’
‘Craig Titmus garners rave reviews for his life sciences adroitness. “He is generous with his time, experience and perspectives, incredibly knowledgeable and always helps us think through the commercial aspects of what we are trying to achieve. He has become a true strategic partner, helping clients far beyond the scope of their existing engagements”.’
“Craig Titmus is highly knowledgeable and consistently meets incredibly tight deadlines.”
Sign up to our mailing list to receive Mathys Matters, our monthly newsletter covering the latest IP news, industry insights, events and case law.
If you are interested in receiving quarterly newsletters relevant to our core sector groups - IT & engineering ('Inside Wires') and life sciences & chemistry ('Under the Microscope') - please select your preference(s) below:
Please select your practice area(s) of interest: